Natera partners with Eledon to supply Prospera monitoring for planned Phase 3 kidney transplant trial

Natera, Inc.
Eledon Pharmaceuticals, Inc.

Natera, Inc.

NTRA

0.00

Eledon Pharmaceuticals, Inc.

ELDN

0.00
  • Natera entered a strategic partnership with Eledon to use Prospera as the exclusive dd-cfDNA monitoring assay in a planned Phase 3 kidney transplant trial.
  • Eledon targets trial initiation in late 2026; enrollment set at about 600 kidney transplant recipients across more than 100 centers globally.
  • Prospera will be used for longitudinal surveillance to track rejection risk while Eledon tests tegoprubart, an investigational anti-CD40L therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260625033359) on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.